PAK1 Antibody (YA6138)
(Synonyms: PAK1; Serine/threonine-protein kinase PAK 1; Alpha-PAK; p21-activated kinase 1; PAK-1; p65-PAK)PAK1 Antibody (YA6138) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PAK1.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, IP, ELISA
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
IP
IP: Immunoprecipitation
|
|---|---|---|---|---|---|
| Dilution Ratio | 1:200-1:1000 | 1:1000-1:5000 | 1:200-1:1000 | 1:5000-1:20000 | 1:50-1:200 |
Product Details
PAK1 Antibody (YA6138) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PAK1.
-
Host Rabbit
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 61 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 61 kDa
Protein A
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
PAK1 is a p21-activated serine/threonine kinase that links Rac/Cdc42 signaling to cell motility, survival, proliferation, cytoskeletal organization, transcription, and translation[1]. Mechanistically, PAK family kinases act as downstream effectors of Rho GTPases, with vertebrate PAKs supporting cytoskeletal remodeling, focal adhesion assembly, cell migration, and synaptic plasticity[2]. In cancer models, PAK1 functions as a signaling node downstream of HGF/MET in pancreatic adenocarcinoma, where PAK1 inhibition blocks cytoskeletal effector signaling, tumor cell motility, tumor growth, and metastasis[3]. In colorectal cancer, Group I Pak inhibition impedes adenoma-to-carcinoma transition by reducing β-catenin activity and suppressing an epithelial-mesenchymal transition program[4]. In neurological disease models, PAK1 knockdown reduces ATXN1 levels in mammalian cells, and pharmacological PAK inhibition decreases ATXN1 levels in an SCA1 mouse model[5]. Compared with related isoforms, PAK1 belongs to Group I PAKs, and inhibitor development must address whether to target one isoform or multiple PAK isoforms[1][5]. For experimental applications, ATP-competitive inhibitors, allosteric inhibitors, and peptide inhibitors provide laboratory tools for studying PAK1 biology and disease contexts[6].
-
Subcellular Localization
Cytoplasm; Cell junction, focal adhesion; Cell projection, lamellipodium; Cell membrane; Cell projection, ruffle membrane; Cell projection, invadopodium; Nucleus, nucleoplasm; Chromosome; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome
-
Expression
Tissue_specificity:Overexpression (protein level) in gastric cancer cells and tissues (PubMed: 25766321) -
Isoforms & Post-Translational Modification
Q13153 has 2 isomers: Q13153-1: 60647 Da (predicted); Q13153-2: 61632 Da (predicted).
Autophosphorylated in trans, meaning that in a dimer, one kinase molecule phosphorylates the other one (PubMed:20417602, PubMed:22153498, PubMed:23633677). Activated by autophosphorylation at Thr-423 in response to a conformation change, triggered by interaction with GTP-bound CDC42 or RAC1 (PubMed:10551809). Activated by phosphorylation at Thr-423 by BRSK2 and by PDPK1 (PubMed:10995762, PubMed:22669945). Phosphorylated by JAK2 in response to PRL; this increases PAK1 kinase activity. Phosphorylated at Ser-21 by PKB/AKT; this reduces interaction with NCK1 and association with focal adhesion sites (PubMed:14585966). Upon DNA damage, phosphorylated at Thr-212 and translocates to the nucleoplasm (PubMed:23260667). Phosphorylated at tyrosine residues, which can be enhanced by NTN1 (By similarity) -
Subunit
Homodimer; homodimerization results in autoinhibition (PubMed:30290153). Active as monomer. Interacts with GIT1 (PubMed:27012601). Component of cytoplasmic complexes, which also contains PXN, ARHGEF7 and GIT1. Interacts with NISCH (By similarity). Interacts with DVL1; mediates the formation of a DVL1, MUSK and PAK1 ternary complex involved in AChR clustering (By similarity). Binds to the caspase-cleaved p110 isoform of CDC2L1 and CDC2L2, p110C, but not the full-length proteins (PubMed:12624090). Interacts with ARHGEF7 (PubMed:16101281, PubMed:27012601). Interacts tightly with GTP-bound but not GDP-bound CDC42/P21 and RAC1 (By similarity). Interacts with SCRIB (PubMed:18716323). Interacts with PDPK1 (PubMed:10995762). Interacts (via kinase domain) with RAF1 (PubMed:11733498). Interacts with NCK1 and NCK2 (PubMed:10026169). Interacts with TBCB (PubMed:15831477). Interacts with BRSK2 (By similarity). Interacts with SNAI1 (PubMed:15833848). Interacts with CIB1 isoform 2 (PubMed:23503467). Interacts with CIB1 (via N-terminal region); the interaction is direct, promotes PAK1 activity and occurs in a calcium-dependent manner. Interacts with INPP5K (PubMed:26940976). Interacts with gamma-tubulin (PubMed:27012601). Interacts with RHOU; the interaction promotes PAK1 activation (PubMed:26598620)
-
SwissProt ID
-
Synonyms
PAK1; Serine/threonine-protein kinase PAK 1; Alpha-PAK; p21-activated kinase 1; PAK-1; p65-PAK
Documentation
[1]. Kichina JV, et al. PAK1 as a therapeutic target. Expert Opin Ther Targets. 2010 Jul;14(7):703-25. [Content Brief]
[2]. Field J, et al. The PAKs come of age: Celebrating 18 years of discovery. Cell Logist. 2012 Apr 1;2(2):54-58. [Content Brief]
[3]. Zhou W, et al. PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition. J Pathol. 2014 Dec;234(4):502-13. [Content Brief]
[4]. Chow HY, et al. Group I Paks are essential for epithelial- mesenchymal transition in an Apc-driven model of colorectal cancer. Nat Commun. 2018 Aug 27;9(1):3473. [Content Brief]
[5]. Bondar VV, et al. PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in spinocerebellar ataxia type 1. Hum Mol Genet. 2018 Aug 15;27(16):2863-2873. [Content Brief]
[6]. Semenova G, et al. Targeting PAK1. Biochem Soc Trans. 2017 Feb 8;45(1):79-88. [Content Brief]
Powered by Bioz
